IRVINE, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate at the upcoming healthcare investor conferences.
Citi BioPharma Conference
Date: Wednesday, September 6 – Thursday, September 7, 2023
Location: Four Seasons, Boston, MA
Baird Global Healthcare Conference
Date: Tuesday, September 12 – Wednesday, September 13, 2023
Location: InterContinental New York Barclay, New York, NY
Leerink Partners Biopharma Summit
Date: Wednesday, September 20 – Friday, September 22, 2023
Location: Rosewood Miramar Beach, Montecito, CA
Cantor Global Healthcare Conference
Date: Tuesday, September 26 – Thursday, September 28, 2023
Location: InterContinental New York Barclay, New York, NY
Links to the presentations will be posted on the Investors section of the Reneo Pharmaceuticals corporate website.
About Reneo Pharmaceuticals
Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, mavodelpar (REN001), is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). Mavodelpar has been shown to increase transcription of genes involved in mitochondrial function, increase fatty acid oxidation, and may increase production of new mitochondria. For additional information, please see reneopharma.com.
Contacts:
Danielle Spangler
Investor Relations
Reneo Pharmaceuticals, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Matthew Purcell, Pharm.D.
Media Inquiries
Russo Partners, LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$3.05 |
| Daily Change: | -0.08 -2.56 |
| Daily Volume: | 62,130 |
| Market Cap: | US$39.160M |
August 12, 2025 May 06, 2025 March 10, 2025 December 10, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
